The Novo Group

The Novo Group is a family of independent companies with a common history and shared values. All Novo Group companies share and benefit from the governance principles stated in the Novo Group Charter, including the Novo Way of Management.

The Novo Nordisk Foundation is a self-governing and profit-making foundation. Its objectives are to provide a stable basis for the commercial and research activities undertaken by the companies in the Novo Group and support scientific, humanitarian and social purposes. The majority of the grants goes to medical and scientific projects as well as to other selected research areas. Among the Foundation's grants are 'The Hallas Møller Scholarship', 'The Novo Nordisk Prize' and funding of the 'STAR project' - a Novo Group programme that aims at increasing knowledge about diabetes care in developing countries.

Novo A/S, the holding company in the Novo Group, was established prior to the demerger of Novo Nordisk in 2000. Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation, and the company's purpose is to manage the Foundation's funds. Besides being the majority shareholder in Novozymes A/S and Novo Nordisk A/S, Novo A/S provides seed, venture and growth equity capital to development stage companies with pioneering scientific ideas within life science.

Novo Nordisk A/S is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk has a workforce of more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.

Novozymes A/S is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business, and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces. Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen A/S.